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Modified vaccinia Ankara (MVA) is being tested in humans as an alternative to the current smallpox vaccine Dryvax. Here, we compare the
magnitude and longevity of protective immune responses elicited by a DNA/MVA HIV-1 vaccine with those elicited by Dryvax using a
monkeypox virus/macaque model. The DNA/MVA vaccine elicited similar levels of vaccinia virus (VV)-specific antibody and 5–10-fold lower
levels of VV-specific cellular responses than Dryvax. This MVA-elicited cellular and humoral immunity was long-lived. A subset of the DNA/
MVA- and Dryvax-vaccinated macaques were subjected to a lethal monkeypox virus challenge at 3 years after vaccination. All of the vaccinated
monkeys survived, whereas the unvaccinated controls succumbed to monkeypox. The viral control correlated with early postchallenge levels of
monkeypox-specific neutralizing antibody but not with VV-specific cellular immune response. Thus, our results demonstrate the elicitation of long
lasting protective immunity for a lethal monkeypox challenge by a DNA/MVA HIV-1 vaccine.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV; Modified vaccinia virus Ankara; DNA/MVA vaccine; Smallpox; Monkeypox; CD8 T cells; Rhesus macaqueIntroduction
Although the World Health Organization certified the
eradication of smallpox from the world in 1979, bioterrorist
threats raise the possibility of the reintroduction of smallpox
into a world, which is no longer being routinely vaccinated
(Gani and Leach, 2001; Henderson, 1999a). There is a serious
need for a new smallpox vaccine because of the incidence of
adverse events to the current vaccine, Dryvax (Enserink, 2002).
In 1968, 15 million people in the US were vaccinated with
Dryvax. Of these, 240 required hospitalization, 9 died and 4
were permanently disabled (Henderson, 1999b). Also, many
people are not qualified to receive Dryvax due to immunode-
ficiency from genetic causes, HIV, or immunosuppressive⁎ Corresponding author. Fax: +1 404 727 7768.
E-mail address: rama@rmy.emory.edu (R.R. Amara).
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doi:10.1016/j.virol.2007.04.010medicinal drugs, skin disorders (particularly eczema), old age,
young age (b1 year) or pregnancy. These groups represent a
significant part of population and must be accounted for in any
reasonable national smallpox vaccination strategy. Thus for
vaccination to become routine in an unexposed population,
smallpox vaccines with fewer side effects need to be developed
(Weltzin et al., 2003).
The correlates for protection against smallpox likely involve
both humoral and cellular immunity. A critical role for humoral
immunity in protection is shown by resistance to smallpox
exposure in individuals with high titers of vaccinia virus (VV)-
specific neutralizing antibodies (Mack et al., 1972; Sarkar et al.,
1975). Evidence for a critical role of cellular immunity comes
from studies in individuals with T cell immunodeficiency. Such
individuals are at high risk for developing disseminated
vaccinia following smallpox vaccinations (O'Connell et al.,
1964; Redfield et al., 1987). Studies in mice evaluating the
74 P. Nigam et al. / Virology 366 (2007) 73–83mechanisms of vaccine-mediated protection against the patho-
genic Western Reserve (WR) vaccinia virus strain have
demonstrated critical protective roles for both VV-specific
antibody (Belyakov et al., 2003; Wyatt et al., 2004a) and T cell
responses (Wyatt et al., 2004a). Also studies with ectromelia
virus demonstrate the importance of antibody (Panchanathan et
al., 2006). These studies suggested a primary role for antibody
and a secondary role for T cells in protection. Recently, studies
in macaques have demonstrated an essential role for VV-
specific antibody for protection against a monkeypox virus
(MPXV) challenge using a macaque model of pathogenic
poxvirus infection (Edghill-Smith et al., 2005b). In addition,
CD4 T cells have been shown to be critical for generating
protective antibody for MPXV in macaques with AIDS
(Edghill-Smith et al., 2005a). However, none of the previous
studies in non-human primates measured the poxvirus-specific
T cell response following MPXV challenge limiting our
understanding about the precise role of cellular immune
response following challenge in the sub-human animal model
of smallpox.
Up to the time of the eradication of smallpox, a number of
efforts were made to develop a safer vaccine (Henderson,
1999b). One of these, further attenuation of a vaccine strain of
vaccinia, resulted in the generation of modified vaccinia
Ankara (MVA). MVAwas attenuated for replication in humans
by over 500 serial passages in chicken embryo fibroblast cells
(Hirsch et al., 1996; Mayr et al., 1978). During these passages,
MVA underwent six large genomic deletions (Antoine et al.,
1998), which eliminated host range genes as well as immune
evasion genes such as soluble receptors for IFN-γ, IFN α/β,
tumor necrosis factor and CC-chemokines (Blanchard et al.,
1998). The block in the replication of MVA in human cells
occurs after the expression of the viral late genes but before
virion morphogenesis (Sutter and Moss, 1992). The unim-
paired late as well as early viral protein synthesis, even in non-
permissive cells, coupled with the deletion of immune evasion
genes, likely contributes to the usefulness of MVA as a safe
yet efficient vaccine. Towards the end of the campaign for the
eradication of smallpox, MVA was safely used in 120,000
humans (Stickl et al., 1974). However, by this time, the
incidence of smallpox was sufficiently low that efficacy could
not be determined.Fig. 1. Schematic for macaque trials. DNA/HIV and MVA/HIV are recombinant
intravenous; i.m, intramuscular; pfu, plaque forming units.There are no comparative studies in humans on VV-specific
immunity raised by Dryvax and MVA. Studies in mice have
compared VV-specific immune responses raised by the Western
Reserve (WR) strain of vaccinia virus with those raised by MVA
(Belyakov et al., 2003; Ramirez et al., 2000; Wyatt et al.,
2004a). These studies demonstrated that the WR virus and
MVA raise similar levels of anti-vaccinia antibody and T cells.
Similarly, recent studies in cynomolgus macaques demonstrated
that two inoculations of MVA elicit similar levels of anti-
vaccinia antibodies as a single inoculation of Dryvax and confer
protection from a lethal MPXV challenge that was administered
by intravenous or respiratory route (Earl et al., 2004; Stittelaar et
al., 2005). The protection conferred by MVAwas similar to that
conferred by Dryvax. These results strongly suggest that MVA
could be a viable alternative to Dryvax.
MVA is also a popular vaccine vector for the expression of
recombinant proteins (Amara et al., 2002b; Barouch et al.,
2001; Earl et al., 2002; Hirsch et al., 1996; Sutter et al., 1994;
Wyatt et al., 1996). We recently demonstrated that an AIDS
vaccine consisting of a DNA prime and recombinant MVA
boost (DNA/MVA SHIV vaccine) raises high titer simian and
human immunodeficiency virus (SHIV)-specific immunity,
which can control a pathogenic SHIV 89.6P challenge in
macaques (Amara et al., 2001, 2002a, 2002b; Sadagopal et al.,
2005). In this report we evaluate the potential of a clade B HIV-
1 DNA/MVA/MVA (DMM) vaccine to elicit long-lived VV-
specific immunity and confer protection from a lethal MPXV
challenge. We longitudinally evaluate the magnitude of VV-
specific cellular and humoral immunity raised by a DMM HIV-
1 vaccine and compare these with the immune responses raised
by a single Dryvax inoculation in rhesus macaques. At 3 years
following vaccination, we conduct a MPXV challenge on a
subset of the DMM- and Dryvax-vaccinated macaques to




Two groups of macaques were used to evaluate the VV-
specific immunity raised by MVA and Dryvax (Fig. 1). The firstDNA and MVA vectors expressing HIV-1 vaccine inserts, respectively. i.v.,
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ing HIV immunogens (Smith et al., 2004b). DNA (600 μg; JS2,
JS7 or JS8) was inoculated on week 0 and MVA (1×108 pfu) on
weeks 8 and 32. Four of the five macaques that received DNA/
JS2 were challenged with 5×107 pfu of MPXV at 156 weeks
post the last MVA inoculation. A second group of 10 macaques
received a single inoculation of∼1×105 pfu of Dryvax. Two of
these 10 macaques were followed for 128 weeks and were
challenged with MPXV.
Temporal VV-specific CD4 and CD8 T cell responses elicited
by the DMM and Dryvax vaccines
Intracellular cytokine staining was used to evaluate the
temporal anti-vaccinia CD4 and CD8 T cell responses in
macaques vaccinated with the DMM HIV-1 and Dryvax
vaccines (Fig. 2). In the DMM-vaccinated macaques, as
expected, VV-specific CD4 and CD8 cells were not detected
until after the 1st MVA boost (Figs. 2B and D). At 1 week after
the first MVA, low frequencies of responding CD8 T cells wereFig. 2. Temporal VV-specific cellular immunity elicited by the DMM and Dryvax vac
an ICS assay. (A) A representative ICS assay. PBMC were stimulated with vaccinia as
were gated on lymphocytes based on the scatter pattern, followed by CD3 expression
represent CD8 cells and left quadrants represent CD4 cells (CD3 positive, CD8 negat
total CD4 cells (left quadrants) or total CD8 cells (right quadrants). (B) VV-specific
Dryvax-vaccinated macaques. (D) VV-specific CD8 response in DMM-vaccinated m
symbol represents an individual macaque. There are 15 animals in the DMM group. F
The numbers on the graphs represent the geometric means for the groups at differendetected in 4 of 5 tested macaques. By 8 weeks, detectable CD8
responses were present in 12 out of the 15 vaccinated macaques.
CD4 responses were below the level of detection in the majority
of the tested monkeys.
Peak cellular responses were observed after the 2nd MVA
when both CD4 and CD8 responses expanded. At 1 week
following the 2nd MVA boost, the magnitude of the CD8
response was 10–15-fold higher than the magnitude of the CD4
response. At this time, 11 out of 15 monkeys had a detectable
CD4 response. These responses ranged from 0.02% to 0.14%
of total CD4 cells and had a geometric mean frequency of
0.03%. In contrast to the CD4 response, CD8 responses were
present in all of the macaques and ranged from 0.06% to 2.1%
of total CD8 cells and had a geometric mean frequency of
0.53%.
The DMM vaccine-elicited VV-specific T cells were long-
lived. CD4 responses underwent only minimal (0–4-fold)
declines over the 3 years of study. The CD8 responses
underwent an initial contraction of 2–25-fold after which they
were stable. At 139 weeks post boost, 7 of 10 tested monkeyscines. VV-specific IFN-γ producing CD4 and CD8 T cells were measured using
described in Materials and methods and stained for CD3, CD8 and IFN-γ. Cells
and analyzed for the expression of CD8 and IFN-γ. Cells in the right quadrants
ive). The frequencies in the upper quadrants are IFN-γ producing cells as a % of
CD4 response in DMM-vaccinated macaques. (C) VV-specific CD4 response in
acaques. (E) VV-specific CD8 response in Dryvax vaccinated macaques. Each
or week 9, data are for 5 macaques and for week 174, data are for 10 macaques.
t time points. The shaded area on the graph represents the level of detection.
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frequency of 0.02%, and 8 of 10 scored for responding CD8
cells with a geometric mean frequency of 0.07%. Two monkeys
failed to score for responding CD4 or CD8 cells.
Analysis of vaccinia-specific T cell responses in macaques
following a single Dryvax vaccination revealed higher levels of
peak CD8 and CD4 T cell responses in Dryvax-vaccinated
macaques than DMM-vaccinated macaques (Figs. 2 and 4).
However, long-term follow-up of vaccinia-specific T cell
responses in 2 of the 10 Dryvax-vaccinated macaques revealed
a greater contraction of CD8 (35–150-fold) and CD4 (250-fold)
T cell responses by 44 weeks following vaccination in Dryvax-
vaccinated macaques compared to the contraction of CD8
(2–25-fold) and CD4 (0–4-fold) T cell responses in DMM-
vaccinated macaques resulting in similar levels of memory
responses in both groups (Fig. 2).
Temporal VV-specific neutralizing antibody elicited by the
DMM vaccine
A GFP/flow cytometry based neutralization assay was used
to evaluate neutralizing antibody to the mature virion (MV)
form of vaccinia virus at various times following vaccination in
macaques vaccinated with the DMM vaccine (Fig. 3A). AssaysFig. 3. VV-specific neutralizing antibody elicited by HIV DMM vaccine. (A) Neutral
measured using a GFP/flow based assay. Each symbol represents an individual macaq
activity observed in the sera of unvaccinated macaques. (B) Neutralizing antibody res
vaccinia immunoglobulin.were performed using serum obtained at 3 weeks following the
first MVA, and 3, 8 and 139 weeks following the second MVA.
At 3 weeks following the first MVA, the titer of the neutralizing
activity was below the level of detection. However, following
the second MVA, these responses rapidly expanded. At 3
weeks following the second MVA, the neutralizing antibody
titer ranged from 285 to 9615 and had a geomean titer of 2253.
By 8 weeks, post the second MVA the titer had contracted
about 2-fold. The DMM vaccine-elicited VV-specific neutra-
lizing antibody response was long-lived and the titers remained
fairly constant with minimal contraction for the next 131
weeks.
Comet reduction assay was performed to evaluate the
potential of VV-specific antibody to prevent the spread of
extracellular form of vaccinia virus (EV) (Appleyard et al.,
1971) (Fig. 3B). The comets represent satellite plaques that
are caused by the spread of released virus by convection
currents (Law et al., 2002). A strong comet reduction was
observed using serum obtained at 3 weeks following the
second MVA (week 35 in the trial). This activity persisted
even at 135 weeks following the second MVA (week 167 in
the trial) albeit at lower levels. Sera obtained from animals
before immunization had no effect on the appearance of the
diffuse comets.izing antibody response against intracellular mature virion form of vaccinia virus
ue. The shaded area on the graph represents the background level of neutralizing
ponse against the extracellular form of vaccinia virus using a comet assay. VIG,
Table 1
Monkeypox viral DNA and number of skin pocks
MPXV genomes/ml blood, log 10 on day Skin pocks
on day
0 2 5 8 13 16 23 8 16
DNA/MVA
RHz7 b3.7 b3.7 b3.7 b3.7 4.1 b3.7 b3.7 N200 0
RAg7 b3.7 b3.7 4.3 5.1 3.9 b3.7 b3.7 N200 0
RRz7 b3.7 b3.7 b3.7 3.9 4.2 b3.7 b3.7 0 0
RJe7 b3.7 b3.7 b3.7 3.7 b3.7 b3.7 b3.7 N200 0
Dryvax
00222 b3.7 b3.7 b3.7 b3.7 b3.7 b3.7 b3.7 0 0
00260 b3.7 b3.7 4.5 b3.7 b3.7 b3.7 b3.7 N200 0
Control
00278 b3.7 4.5 4.6 8.2 ** ** ** N200 **
Rhg8 b3.7 4.5 4.6 6.5 ** ** ** N200 **
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Dryvax and DMM vaccines
At the peak vaccine response Dryvax elicited about 10-times
higher levels of CD4 response than the DMM vaccine (pb0.01)
(Fig. 4A). At the peak vaccine response, the frequency of CD4 T
cells elicited by Dryvax ranged from 0.09% to 1.23% of total
CD4 cells with a geometric mean of 0.58%. These frequencies
are similar to what we previously reported for Dryvax-
vaccinated humans (Amara et al., 2004). Unlike the CD4
response elicited by the DMM vaccine (Fig. 2), the CD4
response elicited by Dryvax underwent about a 5-fold contrac-
tion by 12 weeks as these cells differentiated into memory. After
contraction, it still was 3-fold higher than the memory CD4
responses elicited by the DMM vaccine (pb0.01). However, the
longitudinal data obtained from the two Dryvax-vaccinatedFig. 4. Comparison of VV-specific cellular and humoral responses elicited by
Dryvax, and DMM vaccines in macaques. (A) VV-specific CD4 T cell response.
(B) VV-specific CD8 T cell response. VV-specific IFN-γ producing CD4 and
CD8 T cells were measured using an ICS assay. (C) Vaccinia virus MV-specific
neutralizing antibody response. MV-specific neutralizing antibody response was
measured using GFP based assay. Each symbol represents an individual
macaque. The numbers on the graph represent the geometric means for the group
at different time points. The shaded area on the graph represents the level of
detection. ‘n’ represents the number of animals in the respective group. Peak
CD4 and CD8 responses for Dryvax and DMM represent weeks 2 and 33 of the
respective trials. Memory CD4 and CD8 responses for Dryvax and DMM
represent weeks 12 and 40 of the respective trials. Peak neutralizing antibody
response for Dryvax and DMM represents weeks 2 and 35 of the respective
trials. Memory neutralizing antibody response for Dryvax and DMM represents
weeks 84 and 167 of the respective trials. DMM, DNA/MVA/MVA.
**=Euthanized.animals (Fig. 2) strongly suggest that the VV-specific CD4
response further contracts over time and will be maintained at
levels that are similar to the levels observed in DMM-vaccinated
macaques.
At peak vaccine response, Dryvax elicited a CD8 response
that was about 5-fold higher than those elicited by the DMM
vaccine (pb0.01) (Fig. 4B). The CD8 response elicited by
Dryvax ranged from 0.12% to 5.3% of total CD8 Tcells and had
a geometric mean frequency of 3.5%. Again, these frequencies
are similar to what we previously reported for Dryvax-
vaccinated humans (Amara et al., 2004). The peak CD8
response contracted in both groups as cells differentiated into
memory.
In contrast to the lower peak cellular responses, the levels of
vaccinia MV-specific neutralizing antibody elicited by the
DMM vaccine were similar to the levels elicited by the Dryvax
vaccine (pb0.01) (Fig. 4C). At peak vaccine response, the titer
of vaccinia MV-specific neutralizing antibody response raised
by Dryvax had a geomean of 1090. These titers were about
2-fold lower than the titer of neutralizing antibody elicited by
the DMM vaccine (pb0.05). However, in the memory phase the
Dryvax and DMM groups had similar levels of vaccinia MV-
specific neutralizing antibody. At 85 weeks following Dryvax
or 135 weeks following the second MVA, the titer of
neutralizing antibody had a geomean of 864 and 608 in Dryvax
and DMM groups, respectively.
Protection from a MPXV challenge by the Dryvax and DMM
vaccines
Both the Dryvax and DMM vaccines conferred protection
against a lethal MPXV challenge administered at 2 and one half
(Dryvax) or 3 (DMM) years post vaccination (Table 1). Four of
the 15 DMM-vaccinated macaques, 2 of the 10 Dryvax-
vaccinated macaques and 2 unvaccinated naïve macaques were
challenged with an intravenous inoculation of 5×107 pfu of
MPXV. Only two macaques were included in the Dryvax and
control group because of the availability of historical data for
Table 2
Postchallenge temperature observations
Rectal temperature (°F) on day
0 2 5 8 13 16 23
DNA/MVA
RHz7 102.5 102.3 103.7 101.5 102.0 101.1 101.5
RAg7 100.0 101.1 101.4 102.8 102.6 101.4 101.2
RRz7 100.9 102.0 102.3 102.5 101.8 101.6 100.8
RJe7 101.7 102.0 102.2 101.8 101.5 101.2 101.7
Dryvax
00222 100.6 100.5 101.4 101.6 100.8 100.5 101.0
00260 101.1 102.3 102.2 101.4 100.7 101.1 101.8
Control
00278 101.4 103.5 105.3 102.0**
RHg8 101.7 103.4 103.1 101.8**
**=Euthanized.
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the same facility (Edghill-Smith et al., 2005b). Viremia,
measured as the copy number of MPXV genomes per ml of
blood, and the number of skin lesions were used as measures of
protection. In unvaccinated macaques, viral DNA was readily
detected by day 2 and reached levels greater than 3×106 copies
per ml of blood by day 8. These macaques developed numerous
lesions, became severely ill and were euthanized by day 13.
This outcome was similar to that of 5 historical control
macaques that had been challenged with identical dose andFig. 5. Cellular and humoral immunity, and correlates for protection following M
monkeypox Zaire strain was performed using a plaque reduction assay. (B) VV-specif
using an ICS assay. (C) Correlation between the peak viremia and immune responses
responses at day 8, postchallenge.route of challenge at the same facility (see Tables 2 and 3 of
Edghill-Smith et al., 2005b). In contrast, the DMM-vaccinated
macaques experienced transient low levels of viremia between
days 5 and 13 and developed lesions. Three of the four DMM-
vaccinated macaques developed greater than 200 lesions by day
8. However, these macaques rapidly controlled their viremia
and skin lesions and were healthy by day 16. As expected
(based on the data from the four historical Dryvax-vaccinated
macaques; see Table 1 of Edghill-Smith et al., 2005b), the
Dryvax-vaccinated macaques experienced low to undetectable
levels of viremia. One of the Dryvax-vaccinated macaques
developed greater than 200 lesions by day 8 but rapidly
controlled by day 13.
Rectal temperatures were taken on all of the animals at
various times following challenge as shown in Table 2.
Macaques in the control group demonstrated the ‘typical’
temperature pattern that is normally seen for MPXV infections,
where there is an elevation, peak and severe decrease prior to
the time of euthanasia. In contrast, all vaccinated animals,
except one animal in the DMM group (RHz7), did not
demonstrate elevated temperatures. The macaque RHz7 had
an elevated temperature at day 5 but returned to ‘normal’
temperature by day 8. Similarly, the vaccinated animals
exhibited minimal weight loss (less than 4%), with the
exception of RAg7 that exhibited a 6% weight loss by day
13. This animal was not euthanized because of the low viremia
and small elevation in rectal temperature. However, this animal
recovered rapidly by day 16.PXV challenge. (A) MPXV-specific neutralizing antibody. Neutralization of
ic CD8 Tcell response. VV-specific IFN-γ producing CD8 Tcells were measured
on the day of challenge. (D) Correlation between the peak viremia and immune
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challenge and correlates for protection
To address the relationship between postchallenge humoral
and cellular immune responses and viral control, we measured
the MPXV-specific neutralizing antibody and VV-specific
CD8 and CD4 T cell responses at various times following
challenge (Fig. 5). On the day of challenge, the levels of
MPXV-specific neutralizing antibody were at or below the
level of detection in all vaccinated and unvaccinated macaques
except one DMM and one Dryvax macaque (Fig. 5A).
Following MPXV challenge, the neutralizing antibody
response rapidly expanded in all vaccinated but not unvacci-
nated macaques. At 8 days following challenge, the titer of
MPXV neutralizing antibody was similar in both DMM and
Dryvax groups ranging from 2500 to N10,000. These titers
were at least 10-fold higher compared to the titer in the control
group (pb0.01).
In contrast to the neutralizing activity, the levels of
VV-specific CD8 T cell response were different between DMM
and Dryvax groups following MPXV challenge (Fig. 5B). On
the day of challenge, the VV-specific CD8 response was low to
below the level of detection (0.01%) in vaccinated macaques.
The magnitude of VV-specific CD8 response was higher in the
DMM group compared to Dryvax group. At this time, 3 out of
the 4 vaccinated macaques in the DMM group had CD8
response between 0.25 and 0.77% whereas these responses
were at the level of detection in both macaques in the Dryvax
group. Following MPXV challenge, the VV-specific CD8 T
cells underwent a rapid expansion in the DMM group but not in
the Dryvax group. At day 8 day following challenge, the VV-
specific CD8 response in the DMM group ranged from 0.4 to
2.4% whereas these responses were below 0.03% in the Dryvax
group. Similarly, the CD8 response was below 0.12% in the two
unvaccinated macaques. However, by 16 days following
challenge, the VV-specific CD8 T cell response expanded in
the Dryvax group. In contrast to the CD8 response, the
VV-specific CD4 response did not increase significantly either
in the vaccinated or unvaccinated macaques following MPXV
challenge (data not shown).
No correlation was observed between prechallenge
VV-specific cellular immunity and postchallenge peak viremia
(Fig. 5C). A weak inverse correlation (p=0.07, r=−0.7) bet-
ween prechallenge MPXV-specific neutralizing antibody and
peak viremia was observed. However, this correlation did not
reach statistical significance could be due to the small group
size. A strong inverse correlation between the levels of peak
viral RNA and MPXV-specific neutralizing antibody at day 8
postchallenge was observed (pb0.05, r=−0.8) (Fig. 5D). This
correlation was not observed between the levels of peak viral
RNA and VV-specific CD8 T cell response at day 8 post-
challenge (Fig. 5D).
Discussion
One of the hallmarks of vaccination using the replication
competent vaccinia virus (Dryvax) is the elicitation of long-lived VV-specific cellular and humoral immunity (Amara et
al., 2004; Crotty et al., 2003; Demkowicz et al., 1996;
Hammarlund et al., 2003; Littaua et al., 1992). While the
previous studies demonstrated that the replication defective
MVA can elicit high titers of VV-specific neutralizing
antibody (Earl et al., 2004), the longevity of this response
has not been reported. Here, we evaluated the magnitude and
longevity of VV-specific humoral and cellular immunity
elicited by a recombinant MVA expressing HIV-1 proteins
in macaques. The HIV-1 DMM vaccine elicited high
frequency VV-specific CD8 and CD4 T cell responses and
high titers of VV-specific neutralizing antibody. Two inocula-
tions of MVA were required for eliciting these high levels of
VV-specific immunity. The VV-specific cellular and humoral
immunity elicited by the DMM vaccine was long-lived and
could be detected even after 3 years following vaccination.
Thus, our results clearly demonstrate that the replication
defective MVA can elicit long-lived VV-specific cellular and
humoral immunity in macaques.
Consistent with the long-lived VV-specific immunity elicited
by the DMM vaccine, the DMM-vaccinated macaques were
protected from a lethal MPXV challenge that was administered
3 years after the final immunization. Macaques vaccinated with
the DMM vaccine developed transient low levels of viremia but
rapidly controlled the infection. These results are similar to
those observed with non-recombinant MVA in cynomolgus
macaques (Earl et al., 2004; Stittelaar et al., 2005) suggesting
that the observed low levels of viremia are not due to the use of
a recombinant MVA, but an inherent property of MVA
immunizations. Low levels of viremia were also observed in
one of the two Dryvax-vaccinated macaques. Given the small
group sizes it will be difficult to compare the level of protection
between Dryvax- and DMM-vaccinated macaques. Never-
theless, our results clearly demonstrate that the HIV DMM
vaccine can confer long-lived protection from a lethal MPXV
challenge. Our study demonstrating the ability of MVA to elicit
long-lived protection against a lethal monkeypox challenge is in
good agreement with a parallel study testing for protection in
rhesus macaques vaccinated with the MVA/MVA SHIV vaccine
(Earl et al., 2007). In this study, the MPXV challenge was
administered to macaques that had successfully controlled a
SHIV-89.6P challenge.
For the first time, our study measured the VV-specific
cellular immunity in addition to VV-specific humoral immunity
following the MPXV challenge. This analysis revealed major
differences in the magnitude of VV-specific CD8 T cell
response between Dryvax- and DMM-vaccinated groups and
provided insights about the correlates for protection. The
postchallenge viral control was associated with early expansion
of VV-specific neutralizing antibody rather than VV-specific
CD8 or CD4 T cell response. At day 8 postchallenge all
vaccinated macaques had high levels of MPXV-specific
neutralizing antibody whereas, high frequency of VV-specific
CD8 T cells were observed only in DMM-vaccinated macaques
but not in Dryxax-vaccinated macaques. Despite the presence of
low levels of VV-specific CD8 T cell responses, the Dryvax-
vaccinated macaques were protected from MPXV challenge.
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antibody and a more minor role for VV-specific CD8 and CD4
T cell response in protection against MPXV. These results are
consistent with a previous study that demonstrated a major role
for neutralizing antibody in protection against monkeypox by
depleting specific T cell subsets prior to monkeypox challenge
(Edghill-Smith et al., 2005b).
In contrast to the postchallenge response, following
vaccination the DMM vaccine elicited lower levels of VV-
specific cellular immune responses than Dryvax. At the peak
of the vaccine-raised response, the DMM vaccine raised 5-
fold lower frequencies of CD8 and 10-fold lower frequencies
of CD4 cells than Dryvax. However, 2–3 years following
vaccination, data obtained from very small number of
macaques suggest similar or better persistence of VV-specific
cellular immunity in DMM-vaccinated macaques compared to
Dryvax-vaccinated macaques. Interestingly, these results in
Dryvax-vaccinated macaques are consistent with our observa-
tion in humans following Dryvax vaccination (Amara et al.,
2004). Previous studies comparing the immunogenicity of
MVA and Dryvax in macaques either did not measure the
VV-specific CD4 T cell response (Earl et al., 2004) or did not
distinguish the responding cells into CD4 and CD8 T cells
(Stittelaar et al., 2005). In contrast to the peak cellular
immunity, the peak titers of VV-specific neutralizing and
binding antibody raised by the DMM vaccine were similar, or
higher, than the titers of VV-specific neutralizing antibody
raised by Dryvax. This neutralizing activity was directed
against both MV and EV forms of vaccinia virus. These
results are consistent with the previous studies using Dryvax
and wild type MVA in macaques (Earl et al., 2004; Stittelaar
et al., 2005).
Following MPXV challenge, the number of pocks that we
observed in recombinant MVA-vaccinated macaques was
higher than observed in macaques vaccinated with non-
recombinant MVA by Earl et al. (Earl et al., 2004; Stittelaar et
al., 2005). In our study, 3 out of the four MVA-vaccinated
macaques experienced greater than 200 pocks, whereas the
number of pocks was below 40 in the study by Earl et al.
Similarly, one of the two Dryvax-vaccinated macaques also had
greater than 200 pocks that was higher than that was previously
reported for Dryvax-vaccinated macaques (Edghill-Smith et al.,
2005b). Interestingly, the two vaccinated macaques (one from
each group) that did not exhibit skin pocks also had higher
levels of MPXV-specific neutralizing antibody at the time of
challenge. These results suggest an inverse relationship between
the prechallenge neutralizing antibody and postchallenge pocks.
In addition, there was no correlation between monkeypox
viremia and number of skin pocks in our study. There are
multiple differences between our study and prior studies using
MVA or Dryvax. We used recombinant MVA in rhesus
macaques (Macaca mullata) and challenged 3 years after the
final immunization. The prior MVA study was conducted in
cynomolgus macaques (Macaca fascicularis) using wild type
MVA and challenges were performed at 8 weeks after the final
immunization at a different facility using a different challenge
stock. The prior Dryvax study was conducted in rhesusmacaques at 8 weeks after the final immunization at the same
facility using the same challenge stock. We suggest that the long
time after challenge would have contributed to the observed
higher levels of skin pocks in our study due to the reduction in
neutralizing antibody titers that is known to occur over time.
This is also supported by the fact that VV-specific neutralizing
antibody seems to play a major role in protection against MPXV
challenge.
In conclusion, our results clearly demonstrate that the HIV-1
DMM vaccine elicits long-lived VV-specific cellular and
humoral immune responses that confer durable protection
from a lethal MPXV challenge. They also demonstrate that
VV-specific humoral immunity, but not cellular immunity,
plays a major role for viral control post MPXV challenge. If
the HIV-1 DNA/MVA vaccine proves successful in controlling
HIV/AIDS in humans, our results suggest that it may also be




The JS2, JS7 and JS8 DNA constructs used for DNA
priming were made in our pGA expression vectors that use the
CMV immediate early promoter and the bovine growth
hormone polyadenylation sequence to express RNAs (Amara
et al., 2005; Smith et al., 2004a, 2004b). JS2 and JS7 express
Gag, PR, RT, Env, Tat, Rev and Vpu sequences of clade B
HIV-1 by subgenomic splicing of the RNA expressed by the
vaccine insert, and JS8 expresses a codon-optimized Gag. All
three plasmids were grown in DH5α, purified using Qiagen
endonuclease-free Giga preps, and dissolved in Mg++ and Ca++
free phosphate buffered saline at 0.3 mg per ml.
MVA/HIV vaccine
MVA/HIV 48 was used for boosting (Wyatt et al., 2004b).
This MVA expresses Gag, PR, RT and a C-terminal truncated
form of Env that are from the same sequences used to construct
JS7. MVA/HIV 48 was purified by sedimentation through a
sucrose pad and was resuspended in phosphate buffered saline
at 1×108 pfu per ml.
Macaques and vaccine trials
DMM HIV vaccine trial
Nine Chinese and 6 Indian rhesus macaques were primed
with DNA on week 0 and boosted with MVA/HIV 48 on
weeks 8 and 32 as previously reported (Smith et al., 2004b).
Five macaques received JS2 DNA, 5 received JS7 DNA and 5
received JS8 DNA. Each macaque received 0.6 mg of a test
DNA i.m. using a needle and syringe, one half delivered to the
upper lateral right thigh and one half delivered to the upper
lateral left thigh. All macaques were boosted in the upper
lateral right thigh i.m. with 1 ml of 1×108 pfu of MVA/HIV
48.
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Ten Indian rhesus macaques were primed with Dryvax (the
current smallpox vaccine) on week 0 using the standard human
dose. The Dryvax vaccine was given by scarification, as
recommended by the Centers for Disease Control and
Prevention. Briefly, macaques were inoculated with a bifurcated
needle that held a drop of vaccine virus at a concentration of
approximately 1×108 pfu/ml and that was pressed 15 times into
the skin of the abdomen. This dose represents about 1×105 pfu
as has been estimated previously (Frey et al., 2002).
General procedures for animal care and housing were in
accordance with the National Research Council (NRC) Guide
for the Care and Use of Laboratory Animals (1996) and the
Animal Welfare Standards incorporated in 9CFR Part 3, 1991.
Intracellular Cytokine Staining (ICS) assay
ICS assays were performed as described previously (Amara
et al., 2001, 2004; Speller and Warren, 2002). Briefly,
approximately 1×106 PBMC were stimulated in 5 ml poly-
propylene tubes in RPMI containing 10% fetal bovine serum,
anti-human CD28, anti-human CD49d (1 μg per ml each,
Pharmingen, Inc. San Diego, CA) in 100 μl. VV-specific T cells
were measured using vaccinia virus strain WR. Approximately
2×106 pfu of vaccinia virus strain WR (multiplicity of infection
of 2, MOI) was added in a volume of 100 μl. After 12 h of
incubation at 37 °C, 900 μl of RPMI containing 10% FBS and
monensin (10 μg/ml) was added and cells were cultured for an
additional 3 h at 37 °C at an angle of 5°. At the end of
stimulation, cells were surface stained with fluorchrome
conjugated antibodies to CD8 (clone SK1, Becton Dickinson)
at 8°–10 °C for 30 min, washed once with cold PBS containing
2% FBS and fixed and permeabilized with Cytofix/Cytoperm
solution (Pharmingen, Inc.). Cells were then incubated with
fluorchrome conjugated antibodies to macaque CD3 (clone FN-
18, Biosource Int.) and IFN-γ (clone B27, Pharmingen) in Perm
wash solution (Pharmingen) for 30 min at 4 °C. Cells were
washed twice with Perm wash, once with plain PBS and
resuspended in 1% formalin in PBS. Approximately 200,000
lymphocytes were acquired on the FACScaliber and analyzed
using FloJo software (Treestar Inc. San Carlos, CA). Lympho-
cytes were identified based on their scatter pattern and CD3+,
CD8− cells were considered as CD4 positive T cells and CD3+,
CD8+ cells were considered as CD8 positive T cells. Using this
assay, we could detect VV-specific CD4 and CD8 T cells as low
as 0.01% of the respective total cells. In unvaccinated controls
and pre-vaccination bleeds of vaccinated macaques, the
frequencies of VV-specific CD4 and CD8 T cells were below
0.01%.
Humoral responses
Neutralization assay against the intracellular mature form
(MV) form of vaccinia virus was performed using a
recombinant vaccinia virus strain WR that expresses GFP as
previously described (Earl et al., 2003). Comet reduction assay
was performed to measure the neutralizing antibodies againstextracellular form (EV) of vaccinia virus. Briefly, BSC-1 cells
were infected with the vaccinia virus strain IHD-J, which
produces comet-like satellite plaques due to the release of large
amounts of extracellular virus. After 2 h, monolayers were
washed three times and overlaid with medium containing serum
samples diluted 1:66. After 36–40 h, cells were stained with
crystal violet and photographed.
Neutralizing antibody titer against the MPXV Zaire strain
was performed using a plaque reduction assay. Briefly,
monkeypox virus strain Zaire 79 was diluted in complete
medium (DMEM containing 2% heat-inactivated FBS, 100 U/
ml penicillin, 100 μg/ml streptomycin, 50 μg/ml gentamicin and
10 mM HEPES) to give 2000 PFU/ml. Aliquots of this viral
suspension (100 μl) were incubated with an equal volume of
heat inactivated serum diluted in complete medium (serum
samples were heat activated at 56 °C for 30 min, before dilution)
for 15 h at 4 °C and then adsorbed to confluent Vero E6 cell
monolayers in 24-well plates for 1 h in a 37 °C 5% CO2
incubator. A 0.5-ml semisolid overlay (MEM, 0.5% methyl
cellulose, 2% heat-inactivated FBS, antibiotics) was added to
each well. Plates were incubated in a 37 °C 5% CO2 incubator
for 3 days. Cell monolayers were stained with 0.25 ml of crystal
violet staining solution (0.1% crystal violet, 70% ethanol) for
1 h at room temperature. Plaques were counted and the percent
neutralization was calculated relative to the number of plaques
in the absence of Ab. Titers represent the reciprocal of the
highest dilution resulting in a 50% reduction in the number of
plaques.
Monkeypox virus (MPXV) challenge
MPXV challenges were performed at Southern Research
Institute (Frederick, Maryland, USA). Macaques were chal-
lenge intravenously with 5×107 pfu of MPXV virus (Zaire
strain). The criteria used to assess whether euthanasia should be
implemented included development of pock lesions, MPXV
viremia, pyrexia, anorexia, weight loss, lethargy and mor-
ibundity. These were used in conjunction with other parameters,
such as physical observations and veterinarian recommenda-
tion. Generally, macaques were euthanized if the temperature
was consistently above 103 °F, weight loss greater than 4%, and
viral loads greater than 106 DNA genome copies per ml blood.
In some instances, the presence of too numerous to count lesion
numbers within the oral cavity was taken into consideration
since this hinders eating and leads to weight loss.
Statistical analysis
TheWilcoxon rank sum test was used to compare differences
in T cell and antibody responses between groups. Spearman
rank-correlation was used to determine the correlation between
viral load and neutralizing antibody or CD8 response.
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